Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on expanded insurer coverage for new drug Yeztugo.
Under Armour's weak Q1 sales and tariff pressures lead to a plunge in its stock price.
Firefly Aerospace's successful Nasdaq debut, raising $868M and reaching a valuation close to $10B, reflects strong investor enthusiasm for its space technology.
Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on expanded insurer coverage for new drug Yeztugo.
Under Armour's weak Q1 sales and tariff pressures lead to a plunge in its stock price.
Firefly Aerospace's successful Nasdaq debut, raising $868M and reaching a valuation close to $10B, reflects strong investor enthusiasm for its space technology.